TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20491837

Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (BCP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Deproteinized bovine bone (DBB)
Number of subjects: 11
Study: 18838638

Group type: COMPARATOR
Intervention: Medical management with placebo
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Medical management plus naltrexone therapy
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Medical management plus combined naltrexone and acamprosate therapy
Number of subjects: 1383
Study: 15840994

Group type: EXPERIMENTAL
Intervention: 0.8% isoflurane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.4% isoflurane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tetanic stimulation of the ulnar nerve
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 20
Study: 11859850

Group type: EXPERIMENTAL
Intervention: Second generation oral contraceptive (30 microg ethinylestradiol/150 microg levonorgestrel)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Third generation oral contraceptive (30 microg ethinylestradiol/150 microg desogestrel)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Desogestrel-containing preparations
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Progestagen-only pills (150 microg desogestrel)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptives
Number of subjects: 86

Group type: COMPARATOR
Intervention: Levonorgestrel-containing oral contraceptives
Number of subjects: 86
Study: 10320115

Group type: EXPERIMENTAL
Intervention: Single question about mood
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: 20-item Center for Epidemiologic Studies Depression Screen
Number of subjects: 969

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Case-finding (both instruments combined)
Number of subjects: 969
Study: 8704102

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange
Number of subjects: 0
Study: 2061422

Group type: EXPERIMENTAL
Intervention: 0.25% glycyrrhizin toothpaste
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.50% glycyrrhizin toothpaste
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 40
Study: 6367226

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31103498

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% with fentanyl (RF)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Bupivacaine 0.125% with fentanyl (BF)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Ropivacaine/Fentanyl (RF)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Bupivacaine/Fentanyl (BF)
Number of subjects: 94
Study: 29442177

Group type: EXPERIMENTAL
Intervention: Rotigotine plus MIRT
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rotigotine alone
Number of subjects: 36
Study: 26962749

Group type: EXPERIMENTAL
Intervention: Self-care management intervention including Diabetes Self-care Management booklet, DVD viewing, counseling rehearsal session, and telephone follow-up
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard diabetic educational program (Control)
Number of subjects: 149
Study: 23929692

Group type: EXPERIMENTAL
Intervention: Error Augmentation (EA) training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Simple repetitive practice (Control)
Number of subjects: 26
Study: 21817123

Group type: EXPERIMENTAL
Intervention: Static magnetic stimulation (SMS) of the pelvic floor, 15 static magnets of 800-1200 Gauss, worn for at least 12 hours a day for 3 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo treatment with inert metal disks, same protocol as SMS
Number of subjects: 101
Study: 19346564

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 394

Group type: COMPARATOR
Intervention: Comparison of EQ-5D and SF-6D
Number of subjects: 394
Study: 17161670

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg lafutidine b.d.
Number of subjects: 30
Study: 15142209

Group type: EXPERIMENTAL
Intervention: SRP+500 mg of systemic tetracycline twice/day for 14 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SRP+tetracycline fibers (Actsite) at four selected sites for 10 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 30
Study: 10700052

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Verapamil 5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lidocaine 10 mg
Number of subjects: 100
Study: 9575643

Group type: EXPERIMENTAL
Intervention: Milgamma tablets (50 mg benfothiamine and 0.25 mg cyancobalamine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Neurobex tablets
Number of subjects: 45
Study: 8417806

Group type: EXPERIMENTAL
Intervention: rHuEPO (400 to 1,500 U per kg twice daily [BID] per week)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: rHuEPO (1,000 U/Kg, BID per week) with iron supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Open label rHuEPO administration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Follow-up on percent dense cell determinations
Number of subjects: 9
Study: 2888547

Group type: EXPERIMENTAL
Intervention: SMS 201-995 (50 micrograms)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 2847454

Group type: EXPERIMENTAL
Intervention: 10% glucose infusion with phosphate buffer (10 mmol phosphate buffer/l)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 10% glucose infusion without phosphate supplement
Number of subjects: 16
Study: 31353479

Group type: EXPERIMENTAL
Intervention: Single oral dose of racemic carvedilol 25 mg (CAR)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single oral dose of racemic lercanidipine 20 mg (LER)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single oral doses of CAR plus LER
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (normal renal function)
Number of subjects: 16
Study: 30032171

Group type: EXPERIMENTAL
Intervention: Deferred/intermittent ART
Number of subjects: 10156
Study: 28791477

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Desflurane and Sevoflurane (both)
Number of subjects: 120
Study: 26043025

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg po daily
Number of subjects: 30
Study: 23602424

Group type: COMPARATOR
Intervention: Normal saline lavage (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gentamicin solution lavage (Group 2)
Number of subjects: 40
Study: 20541841

Group type: EXPERIMENTAL
Intervention: 10 mg/day donepezil hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19104004

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 3277

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 3277
Study: 16813139

Group type: EXPERIMENTAL
Intervention: Toothbrush T3 (Comfort Clean - Johnson & Johnson - Reach)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Toothbrush T1 (Colgate Flexível - Colgate)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Toothbrush T2 (Oral B Advantage Control Grip - Oral B)
Number of subjects: 17
Study: 15334279

Group type: EXPERIMENTAL
Intervention: Ciclopirox shampoo
Number of subjects: 0
Study: 10683004

Group type: EXPERIMENTAL
Intervention: Experimental group (specific movement sequence)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo-control group (non-specific movements)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no movements)
Number of subjects: 60
Study: 9100160

Group type: COMPARATOR
Intervention: Libido (3 g twice daily)
Number of subjects: 31
Study: 8468765

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (250 mg every 6 hours for 3 days) followed by oral prednisone (1 mg/kg per day for 11 days)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg/kg per day for 14 days)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Oral placebo for 14 days
Number of subjects: 457
Study: 3963356

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg nalbuphine
Number of subjects: 7
Study: 29461920

Group type: EXPERIMENTAL
Intervention: Creating Change (CC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Seeking Safety (SS)
Number of subjects: 52
Study: 25801662

Group type: EXPERIMENTAL
Intervention: Climate Schools course (Internet-based prevention program)
Number of subjects: 1103

Group type: COMPARATOR
Intervention: Control group (health education as usual)
Number of subjects: 1103
Study: 24152821

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 61

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 61
Study: 22385472

Group type: EXPERIMENTAL
Intervention: Acotiamide (100 mg t.i.d.)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 20446587

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 2539

Group type: COMPARATOR
Intervention: Non-aspirin (control group)
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Trapidil 300 mg/day
Number of subjects: 2539

Group type: COMPARATOR
Intervention: No antiplatelets (control group)
Number of subjects: 2539
Study: 18346011

Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Number of subjects: 0
Study: 16673837

Group type: EXPERIMENTAL
Intervention: Depressive symptoms measured using the Center for Epidemiologic Studies Depression Scale (CES-D)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Metabolic control measured by HbA1c, lipids, blood pressure
Number of subjects: 183
Study: 12895190

Group type: EXPERIMENTAL
Intervention: Clomethiazole (68 mg kg(‐1) as a three-phase i.v. infusion over 24 h)
Number of subjects: 1546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1546
Study: 10865417

Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia (IDA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: G6PD deficiency (G6PD def.)
Number of subjects: 28
Study: 9108693

Group type: EXPERIMENTAL
Intervention: Expectations of entitativity for individual targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expectations of entitativity for group targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recall, memory‐judgment correlation, and illusory correlation measures
Number of subjects: 0
Study: 8213104

Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg)
Number of subjects: 1073

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1073
Study: 3747025

Group type: EXPERIMENTAL
Intervention: Doppler technique
Number of subjects: 150

Group type: COMPARATOR
Intervention: Anterior route (standard technique)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Posterior route (standard technique)
Number of subjects: 150
Study: 29635842

Group type: EXPERIMENTAL
Intervention: Mepilex Border Sacrum and Mepilex Heel dressings applied to sacrum and heels (n = 138)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard care (n = 150)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Mepilex Border Sacrum and Mepilex Heel dressings
Number of subjects: 288
Study: 28825195

Group type: EXPERIMENTAL
Intervention: CIM treatments (≥4 treatments, ≤30 days apart)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: CIM treatments (AIC group)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study: 26139583

Group type: EXPERIMENTAL
Intervention: Natriuretic peptide-based screening and collaborative cardiovascular care
Number of subjects: 1054
Study: 23123166

Group type: EXPERIMENTAL
Intervention: Multimodal approach of musculoskeletal and obstetric management (MOM)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Standard obstetric care
Number of subjects: 169
Study: 22319753

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Calcium hydroxide (CH)
Number of subjects: 17
Study: 18489634

Group type: EXPERIMENTAL
Intervention: 10 mg oxycodone/650 mg acetaminophen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg hydrocodone/650 mg acetaminophen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mg oxycodone/325 mg acetaminophen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mg hydrocodone/325 mg acetaminophen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 650 mg acetaminophen
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15972889

Group type: EXPERIMENTAL
Intervention: Surrogate endpoint (tumor response)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard meta-analysis using only true endpoints
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinically meaningful difference in true endpoints
Number of subjects: 0
Study: 14710262

Group type: EXPERIMENTAL
Intervention: Ropivacaine (Group R, n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine (Group B, n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ropivacaine (Group R)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine (Group B)
Number of subjects: 50
Study: 10924865

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 349
Study: 8690107

Group type: EXPERIMENTAL
Intervention: GH‐releasing hormone (GH‐RH) (1 mg/kg body weight)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg by mouth)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GH‐RH plus arginine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Arginine (30 g infused IV over a 30‐minute period)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GH‐RH plus pyridostigmine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Basal hormonal values
Number of subjects: 18

Group type: COMPARATOR
Intervention: Insulin growth factor‐I levels
Number of subjects: 18
Study: 1869595

Group type: COMPARATOR
Intervention: Flosequinan
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 22
Study: 6630328

Group type: EXPERIMENTAL
Intervention: Senokot
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 40
Study: 31955642

Group type: EXPERIMENTAL
Intervention: Paramedic Global Impression of Change (PGIC) Scale
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Diagnosis of cerebral ischemia
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Diagnosis of intracranial hemorrhage
Number of subjects: 1700
Study: 29171557

Group type: EXPERIMENTAL
Intervention: Supervised structured aerobic exercise training programme, routine medication and dietary plan for 25 weeks at 3 days per week
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine medication and dietary plan
Number of subjects: 102
Study: 26606990

Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty (HA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cementless hemiarthroplasty (HA)
Number of subjects: 60
Study: 24033087

Group type: EXPERIMENTAL
Intervention: Hysterosalpingogram (HSG) with lipiodol
Number of subjects: 296
Study: 22959311

Group type: EXPERIMENTAL
Intervention: Bipolar vessel sealing system (BVSS)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 116
Study: 18923193

Group type: EXPERIMENTAL
Intervention: E-mail invitation mode
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retired adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risk-focused message
Number of subjects: 0
Study: 17334275

Group type: EXPERIMENTAL
Intervention: Category fluency (CF) test (animals/min) for illiterates
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Category fluency (CF) test (animals/min) for 1 to 3 years education
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Category fluency (CF) test (animals/min) for 4 to 7 years education
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Category fluency (CF) test (animals/min) for >=8 years education
Number of subjects: 205
Study: 15754699

Group type: EXPERIMENTAL
Intervention: Treatment with oral laxative (lactulose 66.7%), metronidazole, and topical glyceryl-trinitrate ointment at 0.2% pre and postoperative
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11600528

Group type: EXPERIMENTAL
Intervention: Sustained release recombinant human GH at 1.5 mg/kg once monthly
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sustained release recombinant human GH at 0.75 mg/kg twice monthly
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sustained release recombinant human GH
Number of subjects: 74

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 74
Study: 9849385

Group type: EXPERIMENTAL
Intervention: Ultrasound transmission velocity (UTV)
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Simultaneous evaluation of BMD and UTV
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: UTV in a selected subgroup of healthy and fractured women paired for BMD (144 pairs)
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Simultaneous use of BMD and UTV
Number of subjects: 759
Study: 8834635

Group type: EXPERIMENTAL
Intervention: Neurotic personality type in patients with alopecia areata
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group of volunteers
Number of subjects: 55
Study: 2213286

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazide with potassium-sparing agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other antihypertensive agents
Number of subjects: 0
Study: 44015

Group type: EXPERIMENTAL
Intervention: Thioproperazine (3 x 3 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiapride (3 x 100 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31605208

Group type: EXPERIMENTAL
Intervention: Mineral water baths (20 g/L)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Mineral water baths (40 g/L)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Mineral water baths (60 g/L)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Tap water procedures
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: All mineral water groups
Number of subjects: 145

Group type: COMPARATOR
Intervention: Mineral water baths vs. tap water
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Single balneotherapy procedure
Number of subjects: 145
Study: 31327147

Group type: EXPERIMENTAL
Intervention: 0.5% Carbomer 980 Gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 27522605

Group type: EXPERIMENTAL
Intervention: Seabuckthorn seed oil at a daily dose of 0.75 ml for 30 days
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sunflower oil placebo
Number of subjects: 106
Study: 25929560

Group type: EXPERIMENTAL
Intervention: Oral enzalutamide 160 mg
Number of subjects: 41
Study: 24469972

Group type: EXPERIMENTAL
Intervention: 300,000 IU intramuscular cholecalciferol
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 25,000 IU oral cholecalciferol monthly
Number of subjects: 153

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 153
Study: 22930004

Group type: EXPERIMENTAL
Intervention: 10 000 IU hCG and standard luteal phase support (Protocol A)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin 0.2 mg) followed by 1500 IU hCG 35 h after triggering final oocyte maturation and standard luteal phase support (Protocol B)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin 0.2 mg) and standard luteal phase support (Protocol C)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin 0.2 mg) without luteal phase support (Protocol D)
Number of subjects: 4
Study: 20616746

Group type: EXPERIMENTAL
Intervention: Flortec (Lactobacillus paracasei B 21060)
Number of subjects: 174

Group type: COMPARATOR
Intervention: FlorVis GG (lactobacillus GG)
Number of subjects: 174
Study: 17572248

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength training
Number of subjects: 812
Study: 16079649

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 11777363

Group type: EXPERIMENTAL
Intervention: Ginkgo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: St. John's wort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginseng
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echinacea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saw palmetto
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 0
Study: 10597869

Group type: EXPERIMENTAL
Intervention: Ebastine 10mg once daily for 2 to 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebastine 20mg once daily for 2 to 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebastine 10mg twice daily for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebastine 20mg once daily for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7703058

Group type: EXPERIMENTAL
Intervention: Vein patch closure
Number of subjects: 27

Group type: COMPARATOR
Intervention: Primary CEA closure
Number of subjects: 27
Study: 2199643

Group type: EXPERIMENTAL
Intervention: Similac Special Care formula with a 50:50 carbohydrate blend of glucose polymers and lactose (n = 8)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Similac Special Care formula with 100% carbohydrate as lactose (n = 10)
Number of subjects: 18
Study: 949102

Group type: EXPERIMENTAL
Intervention: Enflurane (Ethrane)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 13